Kyrgyzstan, a country in Central Asia, has been experiencing a rise in the prevalence of diabetes in recent years. This has led to an increase in demand for anti-diabetes drugs in the country.
Customer preferences: In Kyrgyzstan, there is a growing preference for oral anti-diabetes drugs over insulin injections. This is due to the convenience and ease of use of oral medications. Additionally, there is a preference for generic drugs due to their affordability compared to branded drugs.
Trends in the market: The anti-diabetes drugs market in Kyrgyzstan is expected to grow due to the increasing prevalence of diabetes in the country. The market is also expected to witness a shift towards newer and more innovative drugs that offer better efficacy and safety profiles. However, the market is also expected to face challenges such as the lack of access to healthcare facilities in rural areas and the high cost of some of the newer drugs.
Local special circumstances: Kyrgyzstan is a low-income country with a healthcare system that is still developing. The country has a high burden of communicable diseases and faces challenges in providing adequate healthcare to its population. This has led to a lack of awareness and education about diabetes, which in turn has contributed to the rise in prevalence of the disease. Additionally, the country has a large rural population with limited access to healthcare facilities, which further exacerbates the problem.
Underlying macroeconomic factors: Kyrgyzstan has a small and open economy that is heavily dependent on remittances from migrant workers. The country has been facing economic challenges in recent years, which has led to a decline in healthcare spending. This has further strained the healthcare system and limited access to healthcare services for the population. Despite these challenges, the government has taken steps to improve healthcare infrastructure and increase access to healthcare services, which is expected to benefit the anti-diabetes drugs market in the long run.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
